US › Healthcare

Longeveron LLC (LGVN)

US · Healthcare · Biotechnology

$0.74+1.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$398,000
Revenue YoY
+4.5%
Net profit
$-4.7M
Profit YoY
+5.5%
EPS
$-0.19
EPS estimate
$-0.17
Net margin
-1,189.9%

EPS came in at -0.19 against a street estimate of -0.17 — a miss of 11.8%.

Key statistics

Market cap
$22.2M
Forward P/E
0.0
P/B
1.38
Book value
$0.52
EPS (TTM)
$-1.14
52-week high
$1.75
52-week low
$0.47
50-day MA
$0.71
200-day MA
$0.73
Beta
-0.36

Analyst view

Analysts rate Longeveron LLC a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.15.

Shareholding

Insiders
9.32%
Institutions
11.95%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.72%
Vanguard Group Inc1.58%
Millennium Management LLC1.41%
BlackRock Inc0.71%
Geode Capital Management, LLC0.64%
ADAR1 Capital Management LLC0.63%
Jane Street Group LLC0.59%
HRT FINANCIAL LLC0.38%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Longeveron LLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.